Classical RAS proteins are not essential for paradoxical ERK activation induced by RAF inhibitors

RAF inhibitors unexpectedly induce ERK signaling in normal and tumor cells with elevated RAS activity. Paradoxical activation is believed to be RAS dependent. In this study, we showed that LY3009120, a pan-RAF inhibitor, can unexpectedly cause paradoxical ERK activation in KRAS -dependent lung cance...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 119; no. 5
Main Authors Lai, Lick Pui, Fer, Nicole, Burgan, William, Wall, Vanessa E, Xu, Bingfang, Soppet, Daniel, Esposito, Dominic, Nissley, Dwight V, McCormick, Frank
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 01.02.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:RAF inhibitors unexpectedly induce ERK signaling in normal and tumor cells with elevated RAS activity. Paradoxical activation is believed to be RAS dependent. In this study, we showed that LY3009120, a pan-RAF inhibitor, can unexpectedly cause paradoxical ERK activation in KRAS -dependent lung cancer cell lines, when KRAS is inhibited by ARS1620, a KRAS inhibitor. Using H/N/KRAS-less mouse embryonic fibroblasts, we discovered that classical RAS proteins are not essential for RAF inhibitor-induced paradoxical ERK signaling. In their absence, RAF inhibitors can induce ERK phosphorylation, ERK target gene transcription, and cell proliferation. We further showed that the MRAS/SHOC2 complex is required for this process. This study highlights the complexity of the allosteric RAF regulation by RAF inhibitors, and the importance of other RAS-related proteins in this process.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
1L.P.L. and N.F. contributed equally to this work.
Author contributions: L.P.L., N.F., D.S., D.E., and F.M. designed research; L.P.L., N.F., W.B., V.E.W., and B.X. performed research; L.P.L., N.F., and F.M. analyzed data; and L.P.L., N.F., D.V.N., and F.M. wrote the paper.
3Present address: Revolution Medicines, Redwood City, CA 94063.
Edited by Jeremy Thorner, Division of Biochemistry, Biophysics & Structural Biology, Department of Molecular and Cell Biology, University of California, Berkeley, CA; received July 22, 2021; accepted November 22, 2021
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.2113491119